Vancomycin administered by continuous infusion should be dosed according to clearance and not based on the patient's body weight P. M. Tulkens1, P. Wallemacq1.

Slides:



Advertisements
Similar presentations
Selected Clinical Calculations
Advertisements

Chapter 19 Critical Care IV Calculations
Pharmacokinetics Questions
Nonlinear pharmacokinetics
Introduction to Prescribing - Part 2 3 rd year Medical Students.
Pharmaceutical Calculations Made Easy Deb Wagner, Pharm D Pharmacy EMS Coordinator.
Dosage Adjustments for Aminoglycosides in Obese Patients Dennis Mungall, Pharm.D. Associate Professor, Pharmacy Practice Director, NTPD OSU,College of.
Practical Pharmacokinetics
Inpatient Pharmacy Vivian Sinkaset, Pharm.D., BCPS Miramar Science Club Guest Speaker April 28, 2010.
Dose Adjustment in Renal and Hepatic Disease
Dosing Regimen Design Infusion regimen.
INTRAVENOUS INFUSION.
Lucile Packard Children’s Hospital
PLASMA CLEARANCE AND RENAL BLOOD FLOW
Quantitative Pharmacokinetics
The General Concepts of Pharmacokinetics and Pharmacodynamics Hartmut Derendorf, PhD University of Florida.
10/13/20151Prof. Mazen Qato. OBJECTIVES 10/13/2015Prof. Mazen Qato2.
From A Physiologic Perspective Chemical Clearance from the Body
Dosing Regimen Individualization Body Size Variability in Body Size Does one size fit all ? If body size is outside the range  25% of normal (for 70.
Population PK-PD Modeling of Anti-Infective Agents
Pharmacokinetics and pharmacodynamics of gentamicin and vancomycin
The General Concepts of Pharmacokinetics and Pharmacodynamics
Multiple dosing: intravenous bolus administration
CLINICAL PHARMACOKINETICS OF LIDOCAINE
Continuous intravenous infusion (one-compartment model)
Clinical Pharmacokinetics of Phenobarbital
Prof. Dr. Henny Lucida, Apt
Pharmacokinetics of Vancomycin in Adult Oncology Patients Hadeel Al-Kofide MS.c; Iman Zaghloul PhD; and Lamya Al-Naim PharmD Department of Clinical Pharmacy,
Clinical Pharmacokinetics of Procainamide Dr. Muslim Suardi Faculty of Pharmacy University of Andalas 2013.
Clinical Pharmacokinetic Equations and Calculations
Case 9 Amikacin in an elderly CKD patient Block 9 : Divine Ramos, Remonte, Reyes, Rivera A, Rivera K, Rivera M, Rogelio, Sagayaga, Santiago, See, Siy,
Dr. Rida Shabbir DPT IPMR KMU 1. Objectives Describe the concept of renal plasma clearance Use the formula for measuring renal clearance Use clearance.
Lecture 2 Clearance, maintenance dose and AUC
The General Concepts of Pharmacokinetics and Pharmacodynamics
Time Plasma Conc (hr) (mg/L) Below limit of detection 1 Compartment IV Analysis & Renal Elimination 500 mg of tobramycin.
Pharmacokinetics 3rd Lecture
1 Vancomycin Pharmacokinetics. 2 Introduction Vancomycin is a glycopeptide antibiotic Mechanism of Action –Exhibits a time dependent or concentration-
Allie punke Pharmacokinetics tutoring Fall 2016
Anticonvulsants: Phenytoin
Isabelle K. Delattre, Françoise Van Bambeke and Paul M. Tulkens
Introduction Results Aim of the study Methods Conclusion References
Allie punke Pharmacokinetics tutoring Fall 2016
Pharmacokinetics of Old and New Glycopeptides
Identification of optimal dose and dosing regimen of clofazimine for the treatment of multi-drug resistant tuberculosis (MDR-TB) based on pharmacokinetic.
Epithelial lining fluid penetration of temocillin administered by continuous infusion in critically ill patients with nosocomial pneumonia. Visée C.1a,
Pharmacokinetics of Vancomycin in Adult Oncology Patients
Pharmacokinetics Tutoring
Lecture-8 Biopharmaceutics
29 Vancomycin Administered by Continuous Infusion
Dosing Regimen Concepts: 2-C, MM, Individualization principles
The machine and its calibration
P-26 ESCMID Conference October 2014, Vienna Austria
Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets.
Anticonvulsants: Valproic acid
Quantitative Pharmacokinetics
The MDRD Study.
Clinical Pharmacokinetics
Clinical Pharmacokinetics
Clinical Pharmacokinetics
John Fanikos, RPh, MBA, Allison E. Burnett, PharmD, Charles E
Pharmacodynamic indices in targeting therapy of critical infections
Gentamicin – principles of use and monitoring
Therapeutic Drug Monitoring chapter 1 part 1
Q1: Drug A is a small and hydrophilic compound that distributes to extracellular fluids only. It has a volume of distribution of 5.6 L in a healthy 70-kg.
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
REFERENCE: APPLIED CLINICAL Slideshow by: lecturer HADEEL DELMAN
The same daily dose of metformin administered as different dosage regimens has differing effects on the concentration–time profile in a patient with CKD.
Université catholique de Louvain, Brussels, Belgium
Presentation transcript:

Vancomycin administered by continuous infusion should be dosed according to clearance and not based on the patient's body weight P. M. Tulkens1, P. Wallemacq1 & H. Derendorf2 1 Louvain Drug Research Institute and Institute of Experimental and Clinical Research, Université catholique de Louvain, Bruxelles, Belgium, 2 Department of Pharmaceutics, University of Florida, Gainesville, United States 6 June 2013 28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29

28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29 The problem Continuous infusion (CI) of vancomcyin is gaining increasing popularity because of facilitated therapeutic drug monitoring and nursing [1].  Van Herendael et al. Ann Intensive Care. 2012; 2:22 In a literature survey, we observed that several authors mention the dosage of vancomycin in "mg per kg of body weight" during the infusion [see e.g. 2,3], which seems to be widely used by clinicians [4]. Wisocki et al. Antimicrob Agents Chemother. 2001; 45:2460-7. Roberts et al. Antimicrob Agents Chemother. 2011; 55:2704-9 Buyle et al. Eur. J. Clin. Microb. Inf. Dis. 2013. 32:763-8 6 June 2013 28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29

28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29 The problem Continuous infusion (CI) of vancomcyin is gaining increasing popularity because of facilitated therapeutic drug monitoring and nursing [1].  Van Herendael et al. Ann Intensive Care. 2012; 2:22 In a literature survey, we observed that several authors mention the dosage of vancomycin in "mg per kg of body weight" during the infusion [see e.g. 2,3], which seems to be widely used by clinicians [4]. Wisocki et al. Antimicrob Agents Chemother. 2001; 45:2460-7. Roberts et al. Antimicrob Agents Chemother. 2011; 55:2704-9 Buyle et al. Eur. J. Clin. Microb. Inf. Dis. 2013. 32:763-8 6 June 2013 28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29

The concept of continuous infusion The aim of continuous infusion is to maintain its serum level at a fixed value (after the loading dose) which is like maintaining the level of water in bath constant. Once a bath is at the desired level (i.e. after the loading dose), maintaining its level constant does not depend upon its volume but of the ratio of tap and drain flows ( which must be equal: in = out…) In = infusion Out = clearance 6 June 2013 28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29

The concept of continuous infusion The aim of continuous infusion is to maintain its serum level at a fixed value (after the loading dose) which is like maintaining the level of water in bath constant. Once a bath is at the desired level (i.e. after the loading dose), maintaining its level constant does not depend upon its volume but of the ratio of tap and drain flows ( which must be equal: in = out…) In = infusion Out = clearance onsen 6 June 2013 28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29

28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29 Where is the error ? (1) Css = Ko/CL (eqn.1) The concentration at steady state is given by where - Ko is the rate if infusion (in mg/h) - CL is the clearance (in L/h) CCrCL = ((140-age) x weight / (Pl.creat. x 72)) x F The creatinine clearance is the calculated one (Cockroft-Gautl) where Pl.creat is the plasma creatinine F is a factor related to sex (1 for male) and this formula includes the weight ! 6 June 2013 28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29

28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29 Where is the error ? (2) If you now divide Ko (rate of infusion) by the weight, you count two times the weight, which leads to incorrect serum levels Css = (Ko/weight) / ((140-age) x weight / (Pl.creat. x 72)) x F The poster show also simulation demonstrating that wile the creatinine clearance is linearly related to the weigh in the Cockroft & Gault's formula serum the levels calculated by equation #1 are not linearly related to the weight used in Cocktroft & Gault's formula to calculate the clearance 6 June 2013 28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29

total daily dose in 24h (mg) Incorrect levels if dividing the daily dose by the weight: example for patients with the same renal function but increasing weights Patient's CCrL (ml/min) Patient's weight (kg) daily dose as mg/kg 1 total daily dose in 24h (mg) Css 2 (mg/L) 100 50 30 1500 16.03 60 1800 19.23 70 2100 22.44 80 2400 25.64 1 as most often but erroneously recommended in the literature (e.g., refs 2-3) for daily dose during the continuous infusion 2 calculated according to equation 1 and using a correction factor of 0.65 (commonly accepted ratio of vancomycin to creatinine clearance [5]) Moellering et al. Ann Intern Med 1981; 94:343-346 6 June 2013 28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29

Conclusions and recommendations Dosing vancomycin by weight (mg/kg) during continuous infusion is a mistake as it leads to incorrect values if patients deviate from ideal body weight. Clinicians wishing to use vancomycin (or any other drug) by continuous infusion should administer first a loading dose calculated on the basis of body weight (typically, for vancomycin, 20 mg/kg over 1h for a patient with normal Vd [0.75 l/kg]); then start the infusion and adjust their dose on the basis of clearance only (typically, for vancomycin, 11 mg/h for CCrCl of 0.1L/h with linear increment or decrement for each variation of 10 %) Practical recommendations are available from ref. [6] and from our web site (http://www.facm.ucl.ac.be/vancomycin) Ampe et al. Int J Antimicrob Agents 2013 May;41(5):439-46 6 June 2013 28th ICC, 5-8th JUne 2013, Yokohama, Japan - Poster discussion #29